MARKET

OVID

OVID

Ovid Therapeutics Inc
NASDAQ
2.420
-0.130
-5.10%
After Hours: 2.420 0 0.00% 19:53 03/24 EDT
OPEN
2.560
PREV CLOSE
2.550
HIGH
2.560
LOW
2.370
VOLUME
2.52M
TURNOVER
--
52 WEEK HIGH
2.720
52 WEEK LOW
0.2425
MARKET CAP
319.14M
P/E (TTM)
-10.2456
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Knight Therapeutics (OtherKHTRF) and Ovid Therapeutics (OVID)
TipRanks · 18h ago
Weekly Report: what happened at OVID last week (0316-0320)?
Weekly Report · 1d ago
Ovid Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 4d ago
Wedbush Maintains Outperform on Ovid Therapeutics, Raises Price Target to $7
Benzinga · 4d ago
Ovid Therapeutics price target raised to $7 from $5 at Wedbush
TipRanks · 4d ago
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding
Seeking Alpha · 4d ago
Regulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval Timelines
TipRanks · 5d ago
Ovid Therapeutics price target raised to $5 from $3 at Roth Capital
TipRanks · 5d ago
More
About OVID
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).

Webull offers Ovid Therapeutics Inc stock information, including NASDAQ: OVID real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OVID stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OVID stock methods without spending real money on the virtual paper trading platform.